337 related articles for article (PubMed ID: 29209536)
1. Activating HER2 mutations as emerging targets in multiple solid cancers.
Connell CM; Doherty GJ
ESMO Open; 2017; 2(5):e000279. PubMed ID: 29209536
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
3. Targeting HER2 expression in cancer: New drugs and new indications.
Vranić S; Bešlija S; Gatalica Z
Bosn J Basic Med Sci; 2021 Feb; 21(1):1-4. PubMed ID: 32530388
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of the HER2 in metastatic breast cancer.
Fang Y; Jiang Y; Wang X; Yang X; Gao Y; Wang J
Tumour Biol; 2014 Dec; 35(12):11851-4. PubMed ID: 25326805
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
6. Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R; Kavuri SM; Searleman AC; Shen W; Shen D; Koboldt DC; Monsey J; Goel N; Aronson AB; Li S; Ma CX; Ding L; Mardis ER; Ellis MJ
Cancer Discov; 2013 Feb; 3(2):224-37. PubMed ID: 23220880
[TBL] [Abstract][Full Text] [Related]
7. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
8. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.
Wang SE; Yu Y; Criswell TL; Debusk LM; Lin PC; Zent R; Johnson DH; Ren X; Arteaga CL
Oncogene; 2010 Jun; 29(23):3335-48. PubMed ID: 20383197
[TBL] [Abstract][Full Text] [Related]
10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
11. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents.
Kang JX; Li C; Cheng YM; Huang MX; Zhao GK; Jin ZL; Qi XW; Gu J; Ouyang Q
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860909
[TBL] [Abstract][Full Text] [Related]
12. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Parikh A; Atreya C; Korn WM; Venook AP
J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715
[TBL] [Abstract][Full Text] [Related]
13. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.
Friedlaender A; Subbiah V; Russo A; Banna GL; Malapelle U; Rolfo C; Addeo A
Nat Rev Clin Oncol; 2022 Jan; 19(1):51-69. PubMed ID: 34561632
[TBL] [Abstract][Full Text] [Related]
14. The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy.
Peng Y; Tan J
Front Biosci (Landmark Ed); 2023 Aug; 28(8):163. PubMed ID: 37664928
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of neratinib resistance in
Eli LD; Kavuri SM
Cancer Drug Resist; 2022; 5(4):873-881. PubMed ID: 36627899
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
17. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Takahashi K; Ishibashi E; Kubo T; Harada Y; Hayashi H; Kano M; Shimizu Y; Shirota H; Mori Y; Muto M; Ishioka C; Dosaka-Akita H; Matsubara H; Nishihara H; Sueoka-Aragane N; Toyooka S; Hirakawa A; Tateishi U; Miyake S; Ikeda S
Medicine (Baltimore); 2020 Aug; 99(32):e21457. PubMed ID: 32769873
[TBL] [Abstract][Full Text] [Related]
19. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
20. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
